問卷

TPIDB > Principal Investigator

Principal Investigator



篩選

List

7Cases

2025-01-03 - 2028-12-31

Phase III

Active
MAGNITUDE-2: A phase 3, multinational, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of NTLA-2001 in participants with transthyretin amyloid disease (ATTRv-PN), a hereditary polyneuropathy.
  • Condition/Disease

    Transthyretinopathy with hereditary polyneuropathy (ATTRv-PN)

  • Test Drug

    NTLA-2001

Participate Sites
3Sites

Recruiting3Sites

2026-04-01 - 2031-06-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting1Sites

2024-08-01 - 2027-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-03-01 - 2027-11-10

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-07-01 - 2026-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2031-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-02-01 - 2029-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites